27
Gaziano J.M., et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997 Oct 21; 96(8): 2520–2525.
28
Avandia w roku 2010 została wycofana z rynku europejskiego z powodu zaostrzonego ryzyka wystąpienia problemów kardiologicznych (przyp. tłum.).
29
McCarthy M.I. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010 Dec 9; 363(24): 2339–2350. Review.
30
Przemoc strukturalna polega na przemocy wywieranej przez niesprawiedliwe struktury społeczne (przyp. tłum.).
31
Rappaport S.M. Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol. 2011 Jan; 21(1): 5–9.
32
Lichtenstein P., et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000 Jul 13; 343(2): 78–85.
33
Olshansky S.J., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005 Mar 17; 352(11): 1138–1145.
34
Bibbins-Domingo K., et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007 Dec 6; 357(23): 2371–2379.
35
Diabetes Prevention Program Research Group, Knowler W.C., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14; 374(9702): 1677–1686.
36
Lim E.L., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011 Oct; 54(10): 2506–2514.
37
Henry B., Kalynovskyi S. Reversing diabetes and obesity naturally: a NEWSTART lifestyle program. Diabetes Educ. 2004 Jan–Feb; 30(1): 48–50, 55–56, 58–59.
38
Jessani S., et al. Should oral glucose tolerance testing be mandatory following acute myocardial infarction? Int J Clin Pract. 2007 Apr; 61(4): 680–683.
39
Khaw K.T., et al. Association of hemoglobin A1c with cardiovascular disease acute mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004 Sep 21; 141(6): 413–420.
40
Yaffe K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA. 2004 Nov 10; 292(18): 2237–2242.
41
MCI, termin ang., mild cognitive impairment (przyp. tłum.).
42
de la Monte S.M., Wands J.R. Alzheimer’s disease is type 3 diabetes – evidence reviewed. J Diabetes Sci Technol. 2008 Nov; 2(6): 1101–1113.
43
Stein J.L., Jack C.R. Jr, Weiner M.W., Toga A.W., Thompson P.M.; Cardiovascular Health Study; ADNI. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010 Aug; 31 (8): 1326–1339.
44
http://www.acpm.org/LifestyleMedicine.htm.
45
Haffner S.M., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–234.
46
The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010. Apr 22; 362(16): 1463–1476.
47
The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010. Apr 22; 362(16): 1477–1490.
48
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010. Apr 29; 362 (17): 1563–1574.
49
The Cochrane Collaboration – amerykańska niezależna zdrowotna organizacja non-profit działająca na całym świecie i współpracująca z rządami, uniwersytetami, szpitalami i organizacjami charytatywnymi. Nazwana od imienia Archiego Cochrane’a (1909–1988), słynnego brytyjskiego epidemiologa (przyp. tłum.).
50
Taylor F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19: CD004816.
51
Abramson J., Wright J.M. Are lipid-lowering guidelines evidence-based? Lancet. 2007 Jan 20; 369(9557): 168–189.
52
Sirvent P., Mercier J., Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008 Jun; 8(3): 333–338.
53
Kuncl R.W. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009 Oct; 22(5): 506–515. PubMed PMID: 19680127.
54
Tsivgoulis G., et al. Presymptomatic Neuromuscular Disorders Disclosed Following Statin Treatment. Arch Intern Med. 2006; 166: 1519–1524.
55
Preiss D., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 1 Tytuł książki Hillary Clinton 2 W Polsce wg szacunków Polskiego Towarzystwa Badań nad Otyłością oraz Instytutu Żywności i Żywienia, na nadwagę cierpi około 60% Polaków (przyp. tłum.). 3 Garber A.J., et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. 4 DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes 5 Lin S.X., Pi-Sunyer E.X.